PYUSD deposits on Morpho Blue see $90M increase in 30 days
PayPal’s stablecoin is quietly becoming a significant force in decentralized lending. PYUSD deposits on Morpho Blue climbed by $90.7 million in the 30 days leading up to August 21, 2026, a jump that reflects both growing confidence in the stablecoin and the broader maturation of on-chain credit markets.
What’s driving the deposit surge
Morpho Blue allows anyone to create permissionless lending markets, meaning no central committee decides which assets qualify or what the terms look like. That structure makes it attractive for curated vault strategies, where asset managers build yield products on top of the underlying protocol. A vault curated by Sentora had accumulated roughly $110 million in deposits as of mid-June 2026, with the overwhelming majority of that held in PYUSD.
Morpho has also worked with Steakhouse Financial to structure lending arrangements that incorporate real-world asset exposure alongside conventional DeFi yield mechanics. PYUSD’s regulatory profile makes it a natural fit for that audience. The stablecoin maintains a 1:1 peg to the US dollar, backed by deposits and Treasury securities, operates under OCC oversight, and undergoes regular audits by KPMG.
Context: PYUSD’s path to Morpho
Paxos Trust Company launched PYUSD for PayPal in August 2023. PYUSD became operational on Morpho Blue in February 2024, making it the first major stablecoin to anchor a lending market on the platform.
Morpho raised $175 million in a funding round in June 2026, a figure that reflects institutional conviction in the on-chain credit thesis.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
